Lv1
70 积分 2026-07-26 加入
CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas
21分钟前
已完结
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
29分钟前
已完结
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
6小时前
已完结
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
6小时前
已完结
皖公网安备34019202002308
